story of the week
A Review on PCSK9 Inhibition as a New Target for Cholesterol Management
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetologia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
PCSK9 Inhibition: The Dawn of a New Age in Cholesterol Lowering?
Diabetologia 2017 Mar 01;60(3)381-389, D Preiss, M MafhamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.